Pelagos Pharmaceuticals
Pre-clinical biotechnology company developing oral drugs to prevent diseases of aging including obesity, heart failure, sarcopenia, and neurodegenerative diseases.
Location
Houston, Texas, USA
Founded
2021
Investors
1
Categories
biotech, longevity, aging, metabolic-disease, cardiovascular
Notes
Pelagos Pharmaceuticals is developing oral drugs to prevent and treat diseases of aging. The company's approach targets fundamental mechanisms of aging to address multiple age-related conditions including obesity, heart failure, sarcopenia (muscle loss), and neurodegenerative diseases.
As a university spinout, Pelagos leverages academic research to develop novel therapeutics for the growing population affected by age-related diseases.
Team
- Dan Watkin - Chief Executive Officer
Additional Research Findings
- Founded in 2021 in Houston, Texas
- Portfolio company of Portal Innovations
- Stage: Pre-clinical
- University spinout: University of Florida, University of Health Sciences and Pharmacy in St. Louis
- Focus on oral drugs for age-related diseases
- Targeting obesity, heart failure, sarcopenia, neurodegeneration
- Part of growing longevity/healthy aging therapeutic space
- Academic research-based drug development
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |